Complexes of human papillomavirus type 16 E6 proteins form pseudo-death-inducing signaling complex structures during tumor necrosis factor-mediated apoptosis

Journal of Virology

Volumn 83, Issue 1, 2009, Pages 210-227

  Filippova, Maria ^a   Filippov, Valery A ^a   Kagoda, Mercy ^a   Garnett, Theodore ^a,b   Fodor, Nadya ^a   Duerksen Hughes, Penelope J ^a  

^a LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; PROCASPASE 8; PROTEIN E6; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; FAS ANTIGEN; ISOPROTEIN; ONCOPROTEIN; REPRESSOR PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACCELERATION; APOPTOSIS; ARTICLE; CELL PROTECTION; CONTROLLED STUDY; DEGRADATION; HUMAN PAPILLOMAVIRUS TYPE 16; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; VIRUS STRAIN; CELL LINE; HUMAN; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; PROTEIN BINDING;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16;

ANTIGENS, CD95; APOPTOSIS; CELL LINE; HUMAN PAPILLOMAVIRUS 16; HUMANS; ONCOGENE PROTEINS, VIRAL; PROTEIN BINDING; PROTEIN ISOFORMS; REPRESSOR PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 58149374626     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.01365-08     Document Type: Article

References (39)

1. Aggarwal, B. B. 2003. Signalling pathways of the TNF superfamily: a double-edged sword. Nat. Rev. Immunol. 3:745-756.
2. Berumen, J., R. M. Ordonez, E. Lazcano, J. Salmeron, S. C. Galvan, R. A. Estrada, E. Yunes, A. Garcia-Carranca, G. Gonzalez-Lira, and A. Madrigal-de la Campa. 2001. Asian-American variants of human papillomavirus 16 and risk for cervical cancer: a case-control study. J. Natl. Cancer Inst. 93:1325-1330.
3. Birle, D. C., and D. W. Hedley. 2006. Signaling interactions of rapamycin combined with erlotinib in cervical carcinoma xenografts. Mol. Cancer Ther. 5:2494-2502.
4. Chen, M., A. Orozco, D. M. Spencer, and J. Wang. 2002. Activation of initiator caspases through a stable dimeric intermediate. J. Biol. Chem. 277:50761-50767.
5. De la Cruz-Hernandez, E., A. Garcia-Carranca, A. Mohar-Betancourt, A. Duenas-Gonzalez, A. Contreras-Paredes, E. Perez-Cardenas, R. Herrera-Goepfert, and M. Lizano-Soberon. 2005. Differential splicing of E6 within human papillomavirus type 18 variants and functional consequences. J. Gen. Virol. 86:2459-2468.
6. Duerksen-Hughes, P. J., J. Yang, and S. B. Schwartz. 1999. HPV 16 E6 blocks TNF-mediated apoptosis in mouse fibroblast LM cells. Virology 264:55-65.
7. Filippova, M., T. A. Brown-Bryan, C. A. Casiano, and P. J. Duerksen-Hughes. 2005. The human papillomavirus 16 E6 protein can render cells either sensitive or resistant to TNF: effect of dose. Cell Death Differ. 12:1622-1635.
8. Filippova, M., and P. J. Duerksen-Hughes. 2003. Inorganic and dimethylated arsenic species induce cellular p53. Chem. Res. Toxicol. 16:423-431.
9. Filippova, M., M. M. Johnson, M. Bautista, V. Filippov, N. Fodor, S. S. Tungteakkhun, K. Williams, and P. J. Duerksen-Hughes. 2007. The large and small isoforms of human papillomavirus type 16 E6 bind to and differentially affect procaspase 8 stability and activity. J. Virol. 81:4116-4129.
10. Filippova, M., L. Parkhurst, and P. J. Duerksen-Hughes. 2004. The human papillomavirus 16 E6 protein binds to Fas-associated death domain and protects cells from Fas-triggered apoptosis. J. Biol. Chem. 279:25729- 25744.
11. Filippova, M., H. Song, J. L. Connolly, T. S. Dermody, and P. J. Duerksen-Hughes. 2002. The human papillomavirus 16 E6 protein binds to tumor necrosis factor (TNF) R1 and protects cells from TNF-induced apoptosis. J. Biol. Chem. 277:21730-21739.
12. Finzer, P., A. Aguilar-Lemarroy, and F. Rosl. 2002. The role of human papillomavirus oncoproteins E6 and E7 in apoptosis. Cancer Lett. 188:15-24.
13. Garcia-Alai, M. M., K. I. Dantur, C. Smal, L. Pietrasanta, and G. Prat-Gay. 2007. High risk HPV E6 oncoproteins assemble into large oligomers that allow localization of endogenous species in prototypic HPV-transformed cell lines. Biochemistry 46:341-349.
14. Garnett, T. O., and P. J. Duerksen-Hughes. 2006. Modulation of apoptosis by human papillomavirus (HPV) oncoproteins. Arch. Virol. 151:2321-2335.
15. Garnett, T. O., M. Filippova, and P. J. Duerksen-Hughes. 2006. Accelerated degradation of FADD and procaspase 8 in cells expressing human papilloma virus 16 E6 impairs TRAIL-mediated apoptosis. Cell Death Differ. 13:1915-1926.
16. Gaur, U., and B. B. Aggarwal. 2003. Regulation of proliferation, survival and apoptosis by members of the TNF superfamily. Biochem. Pharmacol. 66:1403-1408.
17. Guccione, E., D. Pim, and L. Banks. 2004. HPV-18 E6*I modulates HPV-18 full-length E6 functions in a cell cycle dependent manner. Int. J. Cancer 110:928-933.
18. Hafner, N., C. Driesch, M. Gajda, L. Jansen, R. Kirchmayr, I. B. Runnebaum, and M. Durst. 2008. Integration of the HPV16 genome does not invariably result in high levels of viral oncogene transcripts. Oncogene 27:1610-1617.
19. Hampson, L., H. C. Kitchener, and I. N. Hampson. 2006. Specific HIV protease inhibitors inhibit the ability of HPV16 E6 to degrade p53 and selectively kill E6-dependent cervical carcinoma cells in vitro. Antivir. Ther. 11:813-825.
20. Harper, N., M. Hughes, M. MacFarlane, and G. M. Cohen. 2003. Fas-associated death domain protein and caspase-8 are not recruited to the tumor necrosis factor receptor 1 signaling complex during tumor necrosis factor-induced apoptosis. J. Biol. Chem. 278:25534-25541.
21. Hougardy, B. M., J. H. Maduro, A. G. van der Zee, D. J. de Groot, F. A. van den Heuvel, E. G. de Vries, and S. de Jong. 2006. Proteasome inhibitor MG132 sensitizes HPV-positive human cervical cancer cells to rhTRAIL-induced apoptosis. Int. J. Cancer 118:1892-1900.
22. Hougardy, B. M., A. G. van der Zee, F. A. van den Heuvel, T. Timmer, E. G. de Vries, and S. de Jong. 2005. Sensitivity to Fas-mediated apoptosis in high-risk HPV-positive human cervical cancer cells: relationship with Fas, caspase-8 and Bid. Gynecol. Oncol. 97:353-364.
23. Howley, P. M., K. Munger, H. Romanczuk, M. Scheffner, and J. M. Huibregtse. 1991. Cellular targets of the oncoproteins encoded by the cancer associated human papillomaviruses. Princess Takamatsu Symp. 22:239-248.
24. Jin, Z., and W. S. El-Deiry. 2006. Distinct signaling pathways in TRAIL-versus tumor necrosis factor-induced apoptosis. Mol. Cell. Biol. 26:8136-8148.
25. Kikuchi, K., and S. Yasumoto. 1999. Retention of cell adhesion and growth capability in human cervical cancer cells deprived of cell anchorage. Jpn. J. Cancer Res. 90:867-873.
26. Kim, K. Y., L. Blatt, and M. W. Taylor. 2000. The effects of interferon on the expression of human papillomavirus oncogenes. J. Gen. Virol. 81:695-700.
27. Liu, Y., V. Tergaonkar, S. Krishna, and E. J. Androphy. 1999. Human papillomavirus type 16 E6-enhanced susceptibility of L929 cells to tumor necrosis factor alpha correlates with increased accumulation of reactive oxygen species. J. Biol. Chem. 274:24819-24827.
28. Mantovani, F., and L. Banks. 2001. The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene 20:7874-7887.
29. Micheau, O., and J. Tschopp. 2003. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 114:181-190.
30. Piboonniyom, S. O., S. Duensing, N. W. Swilling, J. Hasskarl, P. W. Hinds, and K. Munger. 2003. Abrogation of the retinoblastoma tumor suppressor checkpoint during keratinocyte immortalization is not sufficient for induction of centrosome-mediated genomic instability. Cancer Res. 63:476-483.
31. Pim, D., and L. Banks. 1999. HPV-18 E6*I protein modulates the E6-directed degradation of p53 by binding to full-length HPV-18 E6. Oncogene 18:7403-7408.
32. Pim, D., P. Massimi, and L. Banks. 1997. Alternatively spliced HPV-18 E6* protein inhibits E6 mediated degradation of p53 and suppresses transformed cell growth. Oncogene 15:257-264.
33. Santin, A. D., P. L. Hermonat, A. Ravaggi, M. Chiriva-Internati, S. Pecorelli, and G. P. Parham. 1998. Radiation-enhanced expression of E6/E7 transforming oncogenes of human papillomavirus-16 in human cervical carcinoma. Cancer 83:2346-2352.
34. Scheffner, M., B. A. Werness, J. M. Huibregtse, A. J. Levine, and P. M. Howley. 1990. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63:1129-1136.
35. Schwock, J., N. A. Pham, M. P. Cao, and D. W. Hedley. 2008. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo. Cancer Chemother. Pharmacol. 61:669-681.
36. Tungteakkhun, S. S., and P. J. Duerksen-Hughes. 2008. Cellular binding partners of the human papillomavirus E6 protein. Arch. Virol. 153:397-408.
37. Vikhanskaya, F., C. Falugi, P. Valente, and P. Russo. 2002. Human papillomavirus type 16 E6-enhanced susceptibility to apoptosis induced by TNF in A2780 human ovarian cancer cell line. Int. J. Cancer 97:732-739.
38. Yang, J., and P. J. Duerksen-Hughes. 1998. A new approach to identifying genotoxic carcinogens: p53 induction as an indicator of genotoxic damage. Carcinogenesis 19:1117-1125.
39. Yeh, W. C., J. L. Pompa, M. E. McCurrach, H. B. Shu, A. J. Elia, A. Shahinian, M. Ng, A. Wakeham, W. Khoo, K. Mitchell, W. S. El-Deiry, S. W. Lowe, D. V. Goeddel, and T. W. Mak. 1998. FADD: essential for embryo development and signaling from some, but not all, inducers of apoptosis. Science 279:1954-1958.